New Alzheimer's Marker Strongly Predicts Mental Decline

Here is a great dementia resource for caregivers and healthcare professionals,

You will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow Alzheimers1 on twitter

Science Daily

A new marker of Alzheimer’s disease can predict how rapidly a patient’s memory and other mental abilities will decline after the disorder is diagnosed, researchers at Washington University School of Medicine in St. Louis have found.

In 60 patients with early Alzheimer’s disease, higher levels of the marker, visinin-like protein 1 (VILIP-1), in the spinal fluid were linked to a more rapid mental decline in the years that followed.
Scientists need to confirm the results in larger studies, but the new data suggest that VILIP-1 potentially may be a better predictor of Alzheimer’s progression than other markers.
“VILIP-1 appears to be a strong indicator of ongoing injury to brain cells as a result of Alzheimer’s disease,” says lead author Rawan Tarawneh, MD, now an assistant professor of neurology at the University of Jordan. “That could be very useful in predicting the course of the disease and in evaluating new treatments in clinical trials."
The study appears March 6 in Neurology.
VILIP-1 was originally identified as a potential indicator of brain cell damage in the laboratory of Jack Ladenson, PhD, the Oree M. Carroll and Lillian B. Ladenson Professor of Clinical Chemistry in Pathology and Immunology at Washington University. Scientists think VILIP-1 serves as a calcium sensor in brain cells. It is released into the cerebrospinal fluid when the cells are injured.
Tarawneh is a former postdoctoral research associate in the laboratory of David Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor and head of Washington University’s Department of Neurology. In an earlier study, she and her colleagues showed that healthy subjects with high levels of VILIP-1 were more likely to develop cognitive impairment and Alzheimer’s disease over a two- to three-year follow-up period.
For the new study, scientists identified patients with very mild or mild Alzheimer’s disease enrolled in studies at the Charles F. and Joanne Knight Alzheimer’s Disease Research Center at Washington University School of Medicine. At the outset, researchers measured levels of VILIP-1 in patients’ spinal fluid and assessed their mental abilities using an extensive battery of tests. The cognitive function testing was repeated annually.

“Memory and other mental abilities declined faster in patients with the highest levels of VILIP-1,” Tarawneh says. “In patients with early symptoms of Alzheimer’s disease, VILIP-1 seems to be at least as good as — and potentially even better than — the other prognostic indicators we used in the study.”
The two additional indicators studied were the proteins amyloid beta and tau. Changes in the spinal fluid levels of those proteins mainly reflect the fact that amyloid beta and tau are starting to form abnormal deposits in the brain. In contrast, VILIP-1 appears to reveal how much damage to brain cells has occurred as a result of brain changes caused by Alzheimer’s.
“These results are intriguing, but we need a larger study to fully understand how the insights provided by VILIP-1 compare to those we can gain from other markers,” Tarawneh says.
She is working with Washington University scientists to standardize the tests that measure VILIP-1 for expanded use in research.
Funding from the National Institutes of Health (NIH), Siemens Health Care Diagnostics and the Charles and Joanne Kn

David Holtzman: Attacking Alzheimer's With a New Test for Amyloid Beta

USNews.com

His SILK test quickly reveals whether medication is working to limit the harmful protein amyloid beta
By January W. Payne



Neuroscientist David Holtzman was captivated by Alzheimer's disease as a medical student. Now the 47-year-old associate director of the Alzheimer's Disease Research Center at the Washington University School of Medicine in St. Louis, Holtzman says he realized that Alzheimer's "was going to be one of the biggest problems that we would face, and it was unsolved." Figuring out how the illness begins and how to prevent or slow it has been his goal ever since.

Holtzman's persistence is paying off. Until now, it typically took about two years to determine whether a new Alzheimer's drug was having an effect. But recently, he and colleagues devised a test that rapidly shows whether an experimental medication has a chance of working. "There aren't good ways without doing a long, expensive trial" to determine this, he says. But with the new test, called stable isotope-linked kinetics, or SILK, "we were able to come up with a technique to figure out over a day or two whether a drug is hitting its target in the brain," he says.

SILK reveals whether the.......read all of Attacking Alzheimer's With a New Test for Amyloid Beta

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,